The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.

Similar Items

• The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
  od: Haiyan Zhou, i dr.
  Izdano: (2020-10-01)
• Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
  od: Zhou, Haiyan, i dr.
  Izdano: (2020)
• Comment on: “Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy” by Zhou et al.
  od: Chen, Tai‐Heng
  Izdano: (2020)
• Antisense Oligonucleotides for the Treatment of Spinal Muscular Atrophy
  od: Porensky, Paul N., i dr.
  Izdano: (2013)
• Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
  od: Catapano, Francesco, i dr.
  Izdano: (2016)